Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sotyktu (Deucravacitinib) Post-Marketing Surveillance in Korean Patients With Moderate-to-Severe Plaque Psoriasis

NCT06258668 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT06258668
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06258668 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sotyktu (Deucravacitinib) Post-Marketing Surveillance in Korean Patients With Moderate-to-Severe Plaque Psoriasis
Lead sponsor
Bristol-Myers Squibb
Phase
Observational
Overall status
Recruiting
Start date
August 21, 2024
Completion date
September 30, 2028
Enrollment
505 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

moderate-to-severe plaque psoriasis